Abstracts tagged "Comorbidity"

Abstract Number: 1279 • ACR Convergence 2023
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Thom Douw³, Manja van Wissen¹, Alfons den Broeder⁴, Dirkjan van Schaardenburg⁵, Cornelia van den Ende⁴ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Leiden University of Applied Sciences, Leiden, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: There is a lack of knowledge about the limitations in activities and participation experienced by a subgroup of people with rheumatoid arthritis (RA) and…
Abstract Number: 2110 • ACR Convergence 2023
Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers
Keigo Hayashi¹, Gregory McDermott¹, Pierre-Antoine Juge², Matthew Moll¹, Michael Cho¹, Tracy J. Doyle¹, Gregory Kinney³, Danielle Sansone-Poe³, Kendra Young³, Paul Dellaripa⁴, Zachary Wallace⁵, Elizabeth Regan⁶, Gary Hunninghake¹, Edwin Silverman¹, Samuel Ash¹, Raul San Jose Estepar¹, George Washko¹ and Jeffrey Sparks⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³University of Colorado Denver, Denver, CO, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶National Jewish Health, Denver, CO, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has known extra-articular manifestations that can result in restrictive and obstructive patterns on pulmonary function measures, especially in smokers. However, investigations…
Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
Abstract Number: 2127 • ACR Convergence 2023
Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer
Maya Swaminathan¹, Sarah Holt², John Gore², Yaw Nyame², Jonathan Wright², George Schade², Ami Shah³, Jeffrey Sparks⁴, Una Makris⁵, Petros Grivas⁶, Maria Suarez-Almazor⁷, Sarah Psutka² and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Department of Urology, University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, ⁷MD Anderson Cancer Center, Houston, TX, ⁸University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
Abstract Number: 0128 • ACR Convergence 2023
Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: To evaluate the burden, longitudinal trends, and drivers of multimorbidity (MM; the presence of ≥2 morbidities) in patients with Systemic Sclerosis (SSc) vs. age-…
Abstract Number: 1335 • ACR Convergence 2023
Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Manja van Wissen¹, Wilfred Peter¹, Alfons den Broeder³, Dirkjan van Schaardenburg⁴, Wilbert van den Hout¹, Cornelia van den Ende³ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Reade, Amsterdam, Netherlands
Background/Purpose: Supervised exercise therapy is an effective and safe treatment option for people with rheumatoid arthritis (RA). However, most studies involve interventions of relatively short…
Abstract Number: 2186 • ACR Convergence 2023
Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life
Matt Makara, Janet Church and Katherine Hammitt, Sjögren’s Foundation, Reston, VA
Background/Purpose: Sjögren's is a serious and systemic autoimmune disease that affects the entire body, including the nervous system. This study aimed to better understand the…
Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Nathalie Carrier¹, Sophie Roux², Hugues Allard-Chamard² and Gilles Boire³, ¹Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ²Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ³Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
Abstract Number: 1646 • ACR Convergence 2022
Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs Initiation in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Nebraska Medical Center, Bellevue, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pain management is challenging in RA where ~60% of patients with well-controlled disease activity still experience bothersome pain. The opioid epidemic in the US…
Abstract Number: 0922 • ACR Convergence 2022
Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
Nuria Barbarroja¹, Carlos Pérez-Sánchez¹, Laura Cuesta-Lopez¹, Miriam Ruiz-Ponce¹, Ivan Arias-de la Rosa¹, Antonio Gonzalez², Eva Perez Pampin³, Chamaida Plasencia-Rodriguez⁴, Ana Martinez-Feito⁴, Rafaela Ortega-Castro¹, Jerusalem Calvo-Gutierrez⁵, Alejandro Balsa⁶, Alejandro Escudero-Contreras¹, Eduardo Collantes¹ and Chary López-Pedrera⁷, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ³Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ⁴Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ⁶Hospital La Paz Institute for Health Research, Madrid, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of suffering cardiovascular disease. The analysis of the cardiovascular and cardiometabolic proteome in RA patients…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…
Abstract Number: 1806 • ACR Convergence 2022
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Naomi Schlesinger¹, Lissa Padnick-Silver², Katie Obermeyer² and Brian LaMoreaux², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
Abstract Number: 1128 • ACR Convergence 2022
The Causal Association Between Osteoarthritis and Common Comorbidities: A Mendelian Randomisation Study
William Thompson¹, Subhashisa Swain², Sizheng Zhao³, Anne Kamps⁴, Carol Coupland⁵, Chang-Fu Kuo⁶, Michael Doherty⁵ and Weiya Zhang⁵, ¹University of Nottingham, Exeter, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Osteoarthritis (OA) is the most common cause of joint pain and a major cause of disability. OA commonly associates with other conditions, such as…
Abstract Number: 1818 • ACR Convergence 2022
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
Naomi Schlesinger¹, ankoor patel¹, Vinod Rustgi¹, Anthony Yeo² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizontherapeutics, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD), but neither the frequency nor severity of NAFLD in gout is well described. Elastography is…

« Previous Page
1
…
7
8
9
10
11
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].